Cataracts Clinical Trial
Official title:
A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification
Verified date | August 2011 |
Source | Bucci Laser Vision Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.
Status | Completed |
Enrollment | 126 |
Est. completion date | January 2010 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects must be 18 years of age or older. - Scheduled for cataract surgery by phacoemulsification. - Subject must be willing to comply with all study requirements and be willing to give informed consent. Exclusion Criteria: - Any subject that has a history of uveitis or active iritis. - Subject can have no previous eye surgery, with the exception of refractive surgery, but not within 6 months. - No ocular use of prostaglandins within 2 weeks of surgery. - Use of oral, injectable or topical ophthalmic steroids, nonsteroidal anti-inflammatory (NSAIDS) or immunosuppressants within 14 days prior to surgery. - Contraindications to NSAIDS. - Active ocular infection. |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Bucci Laser Vision Institute | Wilkes-Barre | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Frank A. Bucci, Jr., M.D. | Allergan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak Aqueous Penetration | day 4 of treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A | |
Completed |
NCT00405730 -
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
|
Phase 3 |